Van ECK Associates Corp raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,341 shares of the biopharmaceutical company’s stock after buying an additional 5,454 shares during the quarter. Van ECK Associates Corp owned about 0.07% of Regeneron Pharmaceuticals worth $32,345,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in REGN. Fieldpoint Private Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares in the last quarter. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $206,000. Institutional investors and hedge funds own 66.51% of the company’s stock.

In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 427 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $493.43, for a total transaction of $210,694.61. Following the completion of the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,489,719.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Robert E. Landry sold 663 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the sale, the senior vice president now directly owns 10,099 shares of the company’s stock, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Insiders have sold 4,779 shares of company stock valued at $2,248,467 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

A number of analysts have commented on the company. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Leerink Swann reissued an “outperform” rating and issued a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price for the company in a report on Wednesday, August 9th. Goldman Sachs Group Inc reissued a “neutral” rating and issued a $472.00 target price (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Robert W. Baird lowered Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $475.34.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at $384.85 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $41,636.91, a PE ratio of 33.55, a price-to-earnings-growth ratio of 1.52 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the company posted $3.13 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% on a year-over-year basis. equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/van-eck-associates-corp-buys-5454-shares-of-regeneron-pharmaceuticals-inc-regn/1725342.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.